自治疗开始以来两年内使用克拉迪宾的现实世界经验:系统性审查和元分析
Angela Albanese1, Irene Schiavetti2, Maria Pia Sormani2
1Merck Serono S.p.A., An Affiliate of Merck KGaA, Rome, Italy; Department of Health Sciences, University of Genoa, Genoa, Italy.
Multiple sclerosis and related disorders
|August 2, 2025
概括
实践数据显示,克拉德里宾片有效降低多发性硬化症患者的复发率和残疾. 这种口服疗法支持在治疗算法中早期使用,以改善结果.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 克拉迪宾片提供口服选择性免疫复合疗法 (IRT),优先减少B和T淋巴细胞.
- 在两年时间内的两次短年疗程中进行,在3年和4年无需进一步治疗.
- 全球范围内,关于克拉德里宾片有效性的新出现的真实数据正在逐渐可用.
研究的目的:
- 综合现实世界的证据,证明克拉迪瑞宾片在多发性硬化症 (MS) 的疗效.
- 评估年度复发率 (ARR),临床残疾恶化 (CDW) 和没有疾病活动证据 (NEDA-3) 状态.
- 评估早期将克拉德里宾片纳入多发性硬化症治疗策略的可能性.
主要方法:
- 在Scopus,Web of Science和PubMed的综合文献搜索中,查找到2024年2月之前发表的现实世界队列.
- 纳入标准:现实数据,累计剂量为3.5mg/kg的克拉迪宾片,平均24个月的随访时间.
- 使用R包对年度复发率 (ARR),临床残疾恶化 (CDW),MRI确认的病变和NEDA-3状态的元分析.
主要成果:
- 对11项现实研究 (152项初始出版物) 的元分析显示,ARR (0.13) 和ARR与基线 (0.81) 相比显著减少.
- 对临床残疾恶化 (0.13),MRI无病状态 (0.72) 和NEDA-3状态 (0.59) 观察到的有利结果.
- 在大多数结果中发现了高异质性 (I2 > 90%),表明现实数据的变化.
结论:
- 现实世界的证据表明,克拉德里宾片在治疗多发性硬化症方面表现出良好的疗效.
- 尽管现实世界数据的概括性存在差异,但研究结果支持在MS治疗算法中早期考虑克拉德里宾片.
- 在减少复发和控制疾病活动方面观察到的好处加强了克拉迪在MS治疗中的作用.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
233
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
233
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K


